Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Oncology Venture. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Oncology Venture's earnings available for a low price, and how does
this compare to other companies in the same industry?
Oncology Venture is not considered high growth as it is expected to be loss making for the next 1-3 years.
Oncology Venture's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oncology Venture's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Oncology Venture's finances.
The net worth of a company is the difference between its assets and liabilities.
Oncology Venture's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Oncology Venture's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Oncology Venture's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Peter Buhl Jensen, Adj Professor, MD, PhD serves as Chief Executive Officer and Member of Executive Board at Medical Prognosis Institute A/S. Mr. Jensen is the Founder of Oncology Venture A/S and has been its Chief Executive Officer since 2012. He serves as a Director at Oncology Venture A/S since 2012. He has been the Chief Executive Officer of Oncology Venture ApS since 2012. Mr. Jensen serves as the Chief Executive Officer of TopoTarget UK Limited. He serves as Clinical Scientific Advisor of WntResearch AB. He co-founded TopoTarget A/S in 2000 and served as its Chief Executive Officer until February 23, 2010. He ensured development, approval and launch of the oncology product Totect/Savene in USA and in Europe. He led the establishment of sales forces in both market regions. He served as the Chief of The Laboratory of Experimental Medical Oncology and is a Consultant Medical Oncologist at The National University Hospital, Copenhagen. He is a successful entrepreneur innovating within the drug development field. He was a Senior Consultant at the Department of Oncology at Aalborg Hospital. Mr. Jensen has 15 years of management experience in cancer research and translational drug development. He has significant management experience in cancer research and translational drug development. He is a specialist in internal medicine. He served as the Chairman of WntResearch AB since 2010 and also serves its Director. He served as the Chairman of LiPlasome Pharma ApS. He serves as Director of LiPlasome Pharma ApS, Vecata Invest A/S, AntiAnthra ApS, LiPlasome A/S and Symbion Fonden. He serves as a Director of Medical Prognosis Institute A/S and of Mirrx A/S. He serves as a Director of Vecata A/S and Proof of Concept Board- DTU-KU-Risø. He served as a Director of Affibody Medical AB (publ) since July 4, 2007. He served as a Director of PledPharma AB since 2011. He served as a Director of TopoTarget A/S from 2000 to June 2, 2009. He served as a Director of Aprea AB and Axelar AB. He has published more than 80 papers on cancer and its treatment. He serves as Honorary Professor of Clinical Oncology at Københavns Universitet. Mr. Jensen studied MD from the University of Copenhagen and Gold Medal, Specialist in internal medicine, PhD in preclinical cancer therapeutics evaluation.
Peter's compensation has increased whilst company is loss making.
Peter's remuneration is lower than average for companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Oncology Venture management team is about average.
Dan Von Hoff
Chief Commercial Officer
Chief Financial Officer
Chief Technology Officer
Chief of Clinical Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Oncology Venture board of directors is about average.
Oncology Venture A/S engages in the research and development of anticancer drugs. Its product pipeline includes LiPlaCis, a liposomal formulation of cisplatin, which is in Phase II clinical trials for the treatment of breast and prostate cancer; 2X-121, a PARP inhibitor in Phase II clinical trials for the treatment of breast cancer; Dovitinib, a multi-tyrosine kinase inhibitor; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials for the treatment of breast cancer; and APO010, an immuno-oncology product in Phase I/II clinical trials for the treatment multiple myeloma. The company has a strategic collaboration with the German Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie and the Danish Breast Cancer Corporative Group to develop precision medicine for women's cancers. Oncology Venture A/S was founded in 2012 and is headquartered in Hørsholm, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.